Literature DB >> 28548875

Overweight, obesity and height as risk factors for meningioma, glioma, pituitary adenoma and nerve sheath tumor: a large population-based prospective cohort study.

Markus K H Wiedmann1,2,3, Cathrine Brunborg4, Antonio Di Ieva2, Kristina Lindemann3,5, Tom B Johannesen6, Lars Vatten7, Eirik Helseth1,3, John A Zwart3,8.   

Abstract

BACKGROUND: In 2016, the International Agency for Research on Cancer (IARC) has announced that avoiding body fatness (i.e. overweight and obesity) contributes to prevent meningioma occurrence, but considered the available evidence for glioma inadequate. The association of body fatness with other CNS tumor subgroups is largely unknown.
OBJECTIVES: To assess whether body fatness or body height are associated with risk for meningioma, glioma, pituitary adenoma (PA) or nerve sheath tumor (NST) in a large population-based Norwegian cohort.
METHODS: In this prospective cohort study of 1.8 million Norwegian residents, weight and height were measured at baseline and incident intracranial tumors were subsequently identified by linkage to the Cancer Registry of Norway. Cox regression analyses were performed to estimate risk for each tumor subgroup in relation to anthropometric measures, stratified by sex and in different age groups.
RESULTS: During 54 million person-years of follow-up 3335 meningiomas, 4382 gliomas, 1071 PAs and 759 NSTs were diagnosed. Obesity (BMI ≥30 kg/m2) was not associated with risk for meningioma or glioma, but was significantly associated with risk for PA (HR 1.43; 95% CI 1.09-1.88) compared with the reference group (BMI 20-24.9 kg/m2). For intracranial NSTs, obesity was associated with reduced tumor risk (HR 0.68; 95% CI 0.46-0.99). Body height was associated with increased risk for all four tumor subgroups.
CONCLUSIONS: This study does not confirm overweight or obesity as risk factors for meningioma. Additionally, overweight and obesity can be quite confidently excluded as risk factors for glioma. However, this study indicates that body fatness increases the risk for PA, while it reduces the risk for NST.

Entities:  

Mesh:

Year:  2017        PMID: 28548875     DOI: 10.1080/0284186X.2017.1330554

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  9 in total

Review 1.  Genetic and molecular epidemiology of adult diffuse glioma.

Authors:  Annette M Molinaro; Jennie W Taylor; John K Wiencke; Margaret R Wrensch
Journal:  Nat Rev Neurol       Date:  2019-06-21       Impact factor: 42.937

2.  Factors Associated With Meningioma Detected in a Population-Based Sample.

Authors:  Jane H Cerhan; Alissa M Butts; Jeremy A Syrjanen; Jeremiah A Aakre; Paul D Brown; Ronald C Petersen; Clifford R Jack; Rosebud O Roberts
Journal:  Mayo Clin Proc       Date:  2019-02       Impact factor: 7.616

3.  Adipocyte proteome and secretome influence inflammatory and hormone pathways in glioma.

Authors:  J Almeida; J Costa; P Coelho; V Cea; M Galesio; J P Noronha; M S Diniz; C Prudêncio; R Soares; C Sala; Rúben Fernandes
Journal:  Metab Brain Dis       Date:  2018-10-09       Impact factor: 3.584

4.  Trends and patterns of incidence of diffuse glioma in adults in the United States, 1973-2014.

Authors:  Kai Li; Dan Lu; Yazhou Guo; Changwei Wang; Xiao Liu; Yu Liu; Dezhong Liu
Journal:  Cancer Med       Date:  2018-09-02       Impact factor: 4.452

5.  Mendelian randomization provides support for obesity as a risk factor for meningioma.

Authors:  Hannah Takahashi; Alex J Cornish; Amit Sud; Philip J Law; Linden Disney-Hogg; Lisa Calvocoressi; Lingeng Lu; Helen M Hansen; Ivan Smirnov; Kyle M Walsh; Johannes Schramm; Per Hoffmann; Markus M Nöthen; Karl-Heinz Jöckel; Joellen M Schildkraut; Matthias Simon; Melissa Bondy; Margaret Wrensch; Joseph L Wiemels; Elizabeth B Claus; Clare Turnbull; Richard S Houlston
Journal:  Sci Rep       Date:  2019-01-22       Impact factor: 4.379

6.  Analysis of Related Factors of Tumor Recurrence or Progression After Transnasal Sphenoidal Surgical Treatment of Large and Giant Pituitary Adenomas and Establish a Nomogram to Predict Tumor Prognosis.

Authors:  Yike Chen; Feng Cai; Jing Cao; Feng Gao; Yao Lv; Yajuan Tang; Anke Zhang; Wei Yan; Yongjie Wang; Xinben Hu; Sheng Chen; Xiao Dong; Jianmin Zhang; Qun Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-14       Impact factor: 5.555

7.  Association between height and the risk of primary brain malignancy in adults: a nationwide population-based cohort study.

Authors:  Stephen Ahn; Kyungdo Han; Jung Eun Lee; Sin-Soo Jeun; Yong Moon Park; Wonil Joo; Seung Ho Yang
Journal:  Neurooncol Adv       Date:  2021-07-08

8.  Body mass index and glioma risk: A prospective multicenter study.

Authors:  Chuan Shao; Hui Tang; Xiaoya Wang; Jiaquan He; Pan Wang; Nan Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

9.  Height as a risk factor in meningioma: a study of 2 million Israeli adolescents.

Authors:  Matan Ben-Zion Berliner; Lior Haim Katz; Estela Derazne; Hagai Levine; Lital Keinan-Boker; Alexandra Benouaich-Amiel; Omer Gal; Andrew A Kanner; Yosef Laviv; Asaf Honig; Tali Siegal; Jacob Mandel; Gilad Twig; Shlomit Yust-Katz
Journal:  BMC Cancer       Date:  2020-08-20       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.